Activation of UL16-binding proteins by HDAC2 and repression by HDAC3 in cancer

被引：0
|
作者：
Lopez-Soto, A. [1 ]
Rodriguez-Folgueras, A. [1 ]
Seto, E. [2 ]
Gonzalez, S. [1 ]
机构：
[1] Univ Oviedo, IUOPA, Dept funct Biol, Asturias, Spain
[2] H Lee Moffitt Canc Res Ctr, Tampa, FL USA
来源：
FEBS JOURNAL | 2008年 / 275卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：403 / 403
页数：1
相关论文
共 50 条
  • [1] Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
    Huang, Renhong
    Zhang, Xiaowei
    Sophia, Sadia
    Min, Zhijun
    Liu, Xiaojian
    ANTI-CANCER DRUGS, 2018, 29 (04) : 364 - 370
  • [2] Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
    Seo, Jinwon
    Min, Soo Kee
    Park, Hye-Rim
    Kim, Dong Hoon
    Kwon, Mi Jung
    Kim, Lee Su
    Ju, Young-Su
    JOURNAL OF BREAST CANCER, 2014, 17 (04) : 323 - 331
  • [3] Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
    Mueller, Berit Maria
    Jana, Lisa
    Kasajima, Atsuko
    Lehmann, Annika
    Prinzler, Judith
    Budczies, Jan
    Winzer, Klaus-Juergen
    Dietel, Manfred
    Weichert, Wilko
    Denkert, Carsten
    BMC CANCER, 2013, 13
  • [4] Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
    Berit Maria Müller
    Lisa Jana
    Atsuko Kasajima
    Annika Lehmann
    Judith Prinzler
    Jan Budczies
    Klaus-Jürgen Winzer
    Manfred Dietel
    Wilko Weichert
    Carsten Denkert
    BMC Cancer, 13
  • [5] Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3
    Zhang, XH
    Wharton, W
    Yuan, ZG
    Tsai, SC
    Olashaw, N
    Seto, E
    MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (12) : 5106 - 5118
  • [6] Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells
    Bayat, Sahar
    Derakhshan, Sima Mansoori
    Derakhshan, Neda Mansoori
    Khaniani, Mahmoud Shekari
    Alivand, Mohammad Reza
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (06) : 9172 - 9180
  • [7] HDAC3 But not HDAC2 Mediates Visual Experience-Dependent Radial Glia Proliferation in the Developing Xenopus Tectum
    Gao, Juanmei
    Ruan, Hangze
    Qi, Xianjie
    Tao, Yi
    Guo, Xia
    Shen, Wanhua
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2016, 10
  • [8] HDAC1/HDAC2/HDAC3 mediated RAD51 and FANCD2 expression contribute to the resistance of melanoma cells to alkylating chemotherapeutics
    Krumm, A.
    Barckhausen, C.
    Kuecuek, P.
    Tomaszowski, K. -H.
    Loquai, C.
    Fahrer, J.
    Kraemer, O.
    Kaina, B.
    Roos, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 150 - 150
  • [9] HDAC1/HDAC2/HDAC3 mediated RAD51 and FANCD2 expression contribute to the resistance of melanoma cells to temozolomide and fotemustine
    Roos, W.
    Krumm, A.
    Barckhausen, C.
    Kuecuek, P.
    Tomaszowski, K.
    Loquai, C.
    Fahrer, J.
    Kraemer, O.
    Kaina, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 15 - 15
  • [10] Lack of HDAC1 and HDAC2 promote breast cancer aggressiveness
    Kamarulzaman, N. S.
    Dewadas, H. D.
    Yaacob, N. S.
    Mokhtar, N. F.
    ANNALS OF ONCOLOGY, 2016, 27
12345